Oruka Therapeutics (ORKA) Price & Analysis

Compare

745 Followers

ORKA Stock Chart & Stats

$33.17

-$0.35(-1.84%)

At close: Jan 08 4:00 PM EST

$33.17

-$0.35(-1.84%)

Day’s Range― - ―

52-Week Range$5.49 - $36.53

Previous CloseN/A

Volume71.58K

Average Volume (3M)530.53K

Market Cap

$1.61B

Enterprise Value$1.15B

Total Cash (Recent Filing)$349.15M

Total Debt (Recent Filing)$1.91M

Price to Earnings (P/E)―

Beta0.83

Next Earnings

May 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding48,409,233

10 Day Avg. Volume602,310

30 Day Avg. Volume530,527

Financial Highlights & Ratios

PEG Ratio-0.31

Price to Book (P/B)0.85

Price to Sales (P/S)0.00

P/FCF Ratio-5.61

Enterprise Value/Market Cap0.72

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-10.18

Forecast

1Y Price Target

$60.71

Price Target Upside83.03% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-2.55

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Dosing DifferentiationORKA-002's substantially longer half-life and sustained target inhibition support the possibility of much less frequent maintenance dosing than current therapies, which could drive patient convenience and treatment persistence.

Market OpportunityDermatologist survey indicates a large addressable market for ORKA-001 in moderate-to-severe psoriasis, supporting strong commercial upside if physician willingness to prescribe translates into patient adoption.

Pipeline Advancement And SafetyPlanned randomized Phase 2 programs for ORKA-001 and ORKA-002 combined with favorable early safety findings and no reported serious adverse events create multiple clinical catalysts that could materially improve the company's outlook if study results are positive.

Bears Say

Cash RunwayLimited cash resources relative to current spending create a risk that additional capital will be required to fund ongoing clinical programs, which could put pressure on the stock if financing is needed.

Financing And Dilution RiskThe potential need to raise capital to support development programs introduces dilution risk for existing shareholders and could negatively affect valuation if funding is obtained on unfavorable terms.

Market SentimentNotable short interest reflects investor skepticism and could amplify downside volatility in the shares during periods of negative news or funding uncertainty.

Oruka Therapeutics News

Oruka’s ORKA-001 Extension Study Builds Long-Term Case in Psoriasis Market

Oruka Therapeutics, Inc. ($ORKA) announced an update on their ongoing clinical study. Oruka Therapeutics, Inc. is running an...

3h ago

ORKA

Is ORKA a Buy, Before Earnings?

Oruka Therapeutics, Inc. (ORKA) is scheduled to report 4th quarter earnings on 03/05/2026. Regarding Q4 estimates, Wall Street...

3d ago

ORKA

Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy

Clear Street analyst Kaveri Pohlman believes AbbVie’s (ABBV) plan to bring an extended half-life anti-IL-23 mAb into the...

1M ago

GSK

ABBV

Oruka Therapeutics price target raised to $45 from $42 at Wedbush

Wedbush raised the firm’s price target on Oruka Therapeutics (ORKA) to $45 from $42 and keeps an Outperform...

2M ago

ORKA

Oruka Therapeutics price target raised to $71 from $46 at Clear Street

Clear Street raised the firm’s price target on Oruka Therapeutics (ORKA) to $71 from $46 and keeps a...

2M ago

ORKA

Oruka Therapeutics: Long-Acting IL-17 Platform Drives Upgraded Valuation and Buy Rating

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Oruka Therapeutics and increased the price target...

2M ago

ORKA

Oruka provides updates on Phase 1 trial of ORKA-002, EVERLAST-B ORKA-001 trial

Oruka Therapeutics (ORKA) announced positive interim data from its Phase 1 trial of ORKA-002 and updates from the...

2M ago

ORKA

Oruka Therapeutics initiated with a Buy at UBS

UBS initiated coverage of Oruka Therapeutics (ORKA) with a Buy rating and $50 price target as the analyst...

2M ago

ORKA

ORKA-001 Psoriasis Trial: Fresh Phase 2 Update and What It Means for Investors

Oruka Therapeutics, Inc. ($ORKA) announced an update on their ongoing clinical study. Study Overview Oruka Therapeutics, Inc. is...

3M ago

ORKA

Oruka Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Oruka Therapeutics (ORKA) with an Overweight rating and $75 price target The firm...

3M ago

ORKA

Oruka Therapeutics Appoints Christopher Martin to Board

An announcement from Oruka Therapeutics ( ($ORKA) ) is now available. On December 11, 2025, Oruka Therapeutics, Inc....

3M ago

ORKA

Oruka Therapeutics Reports Q3 2025 Financial Results

Oruka Therapeutics, Inc. ( ($ORKA) ) has released its Q3 earnings. Here is a breakdown of the information...

4M ago

ORKA

Oruka Therapeutics price target raised to $63 from $56 at BTIG

BTIG analyst Julian Harrison raised the firm’s price target on Oruka Therapeutics (ORKA) to $63 from $56 and...

4M ago

ORKA

Oruka Therapeutics initiated with a Buy at Jefferies

Jefferies analyst Roger Song initiated coverage of Oruka Therapeutics (ORKA) with a Buy rating and $45 price target...

4M ago

ORKA

ORKA FAQ

What was Oruka Therapeutics’s price range in the past 12 months?

Oruka Therapeutics lowest stock price was $5.49 and its highest was $36.53 in the past 12 months.

What is Oruka Therapeutics’s market cap?

Oruka Therapeutics’s market cap is $1.61B.

When is Oruka Therapeutics’s upcoming earnings report date?

Oruka Therapeutics’s upcoming earnings report date is May 20, 2026 which is in 75 days.

How were Oruka Therapeutics’s earnings last quarter?

Currently, no data Available

Is Oruka Therapeutics overvalued?

According to Wall Street analysts Oruka Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oruka Therapeutics pay dividends?

Oruka Therapeutics pays a Notavailable dividend of $19.356 which represents an annual dividend yield of N/A. See more information on Oruka Therapeutics dividends here

What is Oruka Therapeutics’s EPS estimate?

Oruka Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Oruka Therapeutics have?

Oruka Therapeutics has 48,409,233 shares outstanding.

What happened to Oruka Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Oruka Therapeutics?

Currently, no hedge funds are holding shares in ORKA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Oruka Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-23.05%

Trailing 12-Months

Asset Growth

956.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oruka Therapeutics

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Oruka Therapeutics (ORKA) Earnings & Revenues

Historic Earnings Reports

ORKA Stock 12 Month Forecast

Average Price Target

$60.71

▲(83.03% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","25":"$25","42":"$42","59":"$59","76":"$76"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$60.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,25,42,59,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.3,37.43076923076923,40.56153846153846,43.69230769230769,46.823076923076925,49.95384615384616,53.08461538461538,56.215384615384615,59.34615384615385,62.47692307692308,65.6076923076923,68.73846153846154,71.86923076923077,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.3,36.33153846153846,38.36307692307692,40.394615384615385,42.426153846153845,44.457692307692305,46.48923076923077,48.52076923076923,50.55230769230769,52.58384615384615,54.61538461538461,56.64692307692308,58.67846153846154,{"y":60.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.3,34.738461538461536,35.176923076923075,35.61538461538461,36.05384615384615,36.49230769230769,36.93076923076923,37.36923076923077,37.80769230769231,38.246153846153845,38.684615384615384,39.12307692307692,39.56153846153846,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.62,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.17,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.67,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >